Giles T D, Sander G E, Roffidal L E, Quiroz A C, Mazzu A L
Department of Medicine, Louisiana State University School of Medicine, New Orleans 70112.
Am J Hypertens. 1992 Dec;5(12 Pt 1):875-9. doi: 10.1093/ajh/5.12.875.
The effects of the calcium antagonist nitrendipine and the diuretic hydrochlorothiazide on plasma calciotropic hormone concentrations and lumbar bone density were compared during the treatment of hypertension in a randomized, double-blind, 8 week parallel study, followed by a 52 week open label study. There were 32 subjects with stable essential hypertension (sitting diastolic blood pressure > or = 95 mm Hg and < or = 115 mm Hg without medication) without evidence of renal insufficiency or active heart disease. They were randomly assigned to receive either 10 mg nitrendipine twice daily or 50 mg hydrochlorothiazide daily. In order to reach and maintain target blood pressure (diastolic blood pressure < or = 95 mm Hg) during the open label period, the nitrendipine dose was titrated up to 30 mg twice daily, and additional antihypertensive drugs, of differing classes, were added as necessary. Blood samples were analyzed for concentrations of calcium, parathyroid hormone, and calcitonin, and lumbar bone density was determined by dual photon absorptiometry, at the baseline and at 24 and 52 weeks of antihypertensive drug therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
在一项随机、双盲、为期8周的平行研究及随后为期52周的开放标签研究中,比较了钙拮抗剂尼群地平和利尿剂氢氯噻嗪在高血压治疗期间对血浆钙调节激素浓度和腰椎骨密度的影响。共有32例原发性高血压病情稳定(坐位舒张压≥95 mmHg且≤115 mmHg,未用药)且无肾功能不全或活动性心脏病证据的患者。他们被随机分配,分别每日两次服用10 mg尼群地平或每日服用50 mg氢氯噻嗪。为了在开放标签期达到并维持目标血压(舒张压≤95 mmHg),尼群地平剂量滴定至每日两次30 mg,并根据需要添加不同类别的其他降压药物。在基线以及抗高血压药物治疗24周和52周时,采集血样分析钙、甲状旁腺激素和降钙素的浓度,并通过双能光子吸收法测定腰椎骨密度。(摘要截选至250字)